Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Biesecker Lab/Clinical Genomics Section, |
RCV000209958 | SCV000265697 | uncertain significance | Malignant hyperthermia, susceptibility to, 1 | 2013-07-01 | criteria provided, single submitter | research | |
Invitae | RCV001853349 | SCV002171078 | uncertain significance | RYR1-related disorder | 2022-09-01 | criteria provided, single submitter | clinical testing | This sequence change replaces asparagine, which is neutral and polar, with lysine, which is basic and polar, at codon 899 of the RYR1 protein (p.Asn899Lys). This variant is present in population databases (rs201401814, gnomAD 0.04%). This missense change has been observed in individual(s) with idiopathic hyperCKemia and equivocal in vitro contracture test result with halothane and a negative personal and family history for malignant hyperthermia (PMID: 20681998, 24195946). ClinVar contains an entry for this variant (Variation ID: 224375). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt RYR1 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002478756 | SCV002792182 | uncertain significance | Central core myopathy; Malignant hyperthermia, susceptibility to, 1; Congenital multicore myopathy with external ophthalmoplegia; Congenital myopathy with fiber type disproportion; King Denborough syndrome | 2021-07-12 | criteria provided, single submitter | clinical testing | |
Revvity Omics, |
RCV003129811 | SCV003810537 | uncertain significance | not provided | 2021-05-24 | criteria provided, single submitter | clinical testing |